
The Expanded Access Summit®, now in virtual form, is our flagship event and the world’s largest annual conference on pre-market access to medicines. The Summit focuses on feasibility for all stakeholders and the integration of well-designed access programs in the modern clinical development process. We work to to continually establish new best practices, dispel prevailing myths, and break through the most stubborn barriers to innovation.
Janet Woodcock, MD; FDA
Expanded Access 3.0, January 28, 2020
Hilary Marston, MD, MPH; NIAID, NIH
Expanded Access 3.0, January 28, 2020
Michael Kurilla, MD, PhD; NCATS, NIH
Expanded Access 3.0, January 28, 2020
The Expanded Access Summit® was launched in 2017 to provide a best-practices forum for thought leaders from the highest level of leadership in industry, clinical care, patient advocacy, and government. It has since become the world’s largest and most influential annual conference on pre-market access to medicines.
Previous Speakers Include:

Janet WoodCock, MD
Director, Center for Drug Evaluation and Research, FDA

Toni Fauci, MD
Director, National Institute of Allergy and Infectious Diseases (NIAID), NIH

Chris Austin, MD
Director, National Center for Advancing Translational Sciences, NIH

Frank Young, MD, PHD
Executive Vice President Clinical & Reg Affairs, TissueTech Inc.; Former FDA Commissioner, 1984-1989

Marjorie Speers, PhD
Executive Director, Clinical Research Pathways

MICHAEL KURILLA, MD, PHD
Director of the Division of Clinical Innovation, NCATS-NIH

MARC BOUTIN, JD
Chief Executive Officer, National Health Council

SUANNA BRUINOOGE, MPH
Director of Research Strategy, CENTRA, American Society of Clinical Oncology (ASCO)
Each year the Summit examines the four major feasibility factors of pre-market access:
Operational efficiency
Learning outcomes and research value
Financial collaboration, cost recovery, and reimbursement from payers
Alignment with healthcare delivery organizations
Register Now
Expanded Access 4.0 (virtual conference)
April 26-29, 2021
The 4th Annual Expanded Access Summit® The Leading Global Forum on Pre-Market Access to MedicinesType | Early Bird (by March 15) | Standard Pricing |
---|---|---|
Corporate | $650 | $895 |
Health System, Gov’t, Non-Profit | $150 | $200 |
Public (Guest Pass) | $50 | $60 |
Entrepreneur | Contact us | -- |
- Four hours of live programming each day
- Access to “on-demand” premium content (explainers, case interviews, etc.)
- Separate “Innovator Showcase” presentations at the end of each live broadcast
- Interactive exhibits
- Breakout chat and discussion groups
- One-on-One Partnering event
2020 Sponsors and Partners





















